Antonio Durando

1.6k total citations
42 papers, 976 citations indexed

About

Antonio Durando is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Antonio Durando has authored 42 papers receiving a total of 976 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 23 papers in Cancer Research and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Antonio Durando's work include Breast Cancer Treatment Studies (20 papers), Cancer Treatment and Pharmacology (16 papers) and HER2/EGFR in Cancer Research (11 papers). Antonio Durando is often cited by papers focused on Breast Cancer Treatment Studies (20 papers), Cancer Treatment and Pharmacology (16 papers) and HER2/EGFR in Cancer Research (11 papers). Antonio Durando collaborates with scholars based in Italy, United States and Switzerland. Antonio Durando's co-authors include Riccardo Arisio, Dionyssios Katsaros, Michela Donadio, Lina Mu, Herbert Yu, Lingeng Lu, Mario Preti, Biyun Qian, Saverio Danese and Anna Sapino and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Antonio Durando

41 papers receiving 948 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Antonio Durando Italy 16 516 509 318 158 146 42 976
Anna Cardillo Italy 17 734 1.4× 613 1.2× 252 0.8× 173 1.1× 125 0.9× 29 1.1k
Elisabetta Pietri Italy 15 593 1.1× 364 0.7× 320 1.0× 200 1.3× 87 0.6× 27 909
Rolando Nortilli Italy 18 611 1.2× 266 0.5× 190 0.6× 115 0.7× 81 0.6× 36 808
Encarna Adrover Spain 14 864 1.7× 366 0.7× 297 0.9× 177 1.1× 113 0.8× 40 1.1k
Theresa Gilewski United States 17 818 1.6× 501 1.0× 229 0.7× 153 1.0× 341 2.3× 23 1.3k
R. Ghisini Italy 18 1.0k 2.0× 944 1.9× 280 0.9× 239 1.5× 148 1.0× 34 1.4k
C. Bryce Canada 8 413 0.8× 407 0.8× 142 0.4× 170 1.1× 107 0.7× 15 707
Eloise Scarano Italy 11 489 0.9× 408 0.8× 209 0.7× 106 0.7× 53 0.4× 17 690
Janice F. Eakle United States 9 565 1.1× 265 0.5× 246 0.8× 345 2.2× 78 0.5× 22 805
M.L. Carcangiu Italy 15 390 0.8× 439 0.9× 248 0.8× 117 0.7× 65 0.4× 31 1.1k

Countries citing papers authored by Antonio Durando

Since Specialization
Citations

This map shows the geographic impact of Antonio Durando's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Durando with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Durando more than expected).

Fields of papers citing papers by Antonio Durando

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Durando. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Durando. The network helps show where Antonio Durando may publish in the future.

Co-authorship network of co-authors of Antonio Durando

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Durando. A scholar is included among the top collaborators of Antonio Durando based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Durando. Antonio Durando is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Mastro, Lucia Del, Mauro Mansutti, Giancarlo Bisagni, et al.. (2021). 118O Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella. Annals of Oncology. 32. S407–S408. 1 indexed citations
3.
Lambertini, Matteo, Francesca Poggio, Marco Bruzzone, et al.. (2019). Dose‐dense adjuvant chemotherapy in HER2‐positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. International Journal of Cancer. 147(1). 160–169. 11 indexed citations
4.
Arisio, Riccardo, Fulvio Borella, Mauro Porpiglia, et al.. (2019). Axillary Dissection vs. no Axillary Dissection in Breast Cancer Patients With Positive Sentinel Lymph Node: A Single Institution Experience. In Vivo. 33(6). 1941–1947. 12 indexed citations
5.
Mastro, Lucia Del, Alessia Levaggi, Andrea Michelotti, et al.. (2015). 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial. Breast Cancer Research and Treatment. 155(1). 117–126. 11 indexed citations
6.
7.
Clavarezza, Matteo, Monica Turazza, Enrico Aitini, et al.. (2013). Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. The Breast. 22(4). 470–475. 11 indexed citations
8.
Castellano, Isabella, Elena Allìa, Anna Maria Vandone, et al.. (2010). Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Research and Treatment. 124(3). 607–617. 166 indexed citations
9.
Castellano, Isabella, Caterina Marchiò, Mariano Tomatis, et al.. (2009). Micropapillary ductal carcinoma in situ of the breast: an inter-institutional study. Modern Pathology. 23(2). 260–269. 15 indexed citations
10.
Qian, Biyun, Dionyssios Katsaros, Lingeng Lu, et al.. (2008). High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Research and Treatment. 117(1). 131–140. 213 indexed citations
11.
Montemurro, Filippo, Stefania Redana, Giuseppe Viale, et al.. (2008). Retrospective Evaluation of Clinical Outcomes in Patients with HER2-Positive Advanced Breast Cancer Progressing on Trastuzumab-Based Therapy in the Pre-Lapatinib Era. Clinical Breast Cancer. 8(5). 436–442. 23 indexed citations
12.
Mastro, Lucia Del, Béatrice Dozin, Enrico Aitini, et al.. (2007). Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest–Mammella Intergruppo (GONO-MIG) Group. Annals of Oncology. 19(2). 299–307. 12 indexed citations
13.
Montemurro, Filippo, Marco Gatti, Stefania Redana, et al.. (2006). Concurrent Radiotherapy Does Not Affect Adjuvant CMF Delivery but is Associated with Increased Toxicity in Women with Early Breast Cancer. Journal of Chemotherapy. 18(1). 90–97. 3 indexed citations
14.
Venturini, M., Claudia Bighin, S. Monfardini, et al.. (2005). Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Research and Treatment. 95(1). 45–53. 20 indexed citations
15.
Montemurro, Filippo, R. Faggiuolo, Michela Donadio, et al.. (2004). A Phase II Study of Three-Weekly Docetaxel and Weekly Trastuzumab in HER2-Overexpressing Advanced Breast Cancer. Oncology. 66(1). 38–45. 36 indexed citations
16.
Venturini, Marco, Antonio Durando, Ornella Garrone, et al.. (2003). Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. Cancer. 97(5). 1174–1180. 17 indexed citations
17.
Tampellini, Marco, Alfredo Berruti, G. Gorzegno, et al.. (2001). Independent Factors Predict Supranormal CA 15-3 Serum Levels in Advanced Breast Cancer Patients at First Disease Relapse. Tumor Biology. 22(6). 367–373. 14 indexed citations
18.
Lianidou, Evi, et al.. (1998). Fragment analysis of the p53 gene in ovarian tumors. Clinical Biochemistry. 31(7). 551–553. 1 indexed citations
19.
Geuna, Massimo, Giorgio Palestro, Antonio Durando, et al.. (1996). Relationships between Proliferative Activity and Oncogene Expression in Human Breast Cancera. Annals of the New York Academy of Sciences. 784(1). 555–563. 2 indexed citations
20.
Maina, Giovanni, et al.. (1989). [Uterine hypoplasia and infertility].. PubMed. 41(4). 165–71.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna Cardillo Breakdown of academic impact, for papers by Elisabetta Pietri Breakdown of academic impact, for papers by Rolando Nortilli Breakdown of academic impact, for papers by Encarna Adrover Breakdown of academic impact, for papers by Theresa Gilewski Breakdown of academic impact, for papers by R. Ghisini Breakdown of academic impact, for papers by C. Bryce Breakdown of academic impact, for papers by Eloise Scarano Breakdown of academic impact, for papers by Janice F. Eakle Breakdown of academic impact, for papers by M.L. Carcangiu
Rankless by CCL
2026